Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
Martin E Brown, Rif S El-Mallakh1Department of Neurology, 2Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky, USAAbstract: Eslicarbazepine is a new dibenzazepine antiepileptic agent. It is a high affinity antagonist of the voltage-gat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-03-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/role-of-eslicarbazepine-in-the-treatment-of-epilepsy-in-adult-patients-a4060 |
| _version_ | 1818976458549231616 |
|---|---|
| author | Martin E Brown Rif S El-Mallakh |
| author_facet | Martin E Brown Rif S El-Mallakh |
| author_sort | Martin E Brown |
| collection | DOAJ |
| description | Martin E Brown, Rif S El-Mallakh1Department of Neurology, 2Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky, USAAbstract: Eslicarbazepine is a new dibenzazepine antiepileptic agent. It is a high affinity antagonist of the voltage-gated sodium channel. It is closely related to both carbamazepine and oxcarbazepine. Eslicarbazepine has similar affinity to inactivated sodium channels (channels in just activated neurons) as carbamazepine, and greater efficacy in animal models of seizure than oxcarbazepine. In human placebo-controlled trials of a single daily dose of eslicarbazepine added to other anti-epileptic agents, significant seizure reductions occurred with 800 and 1200 mg daily, with nearly half of the patients experiencing a greater than 50% reduction in seizure frequency. Adverse events (AEs) occurred in over 50% of patients receiving therapeutic doses of eslicarbazepine (compared to 31.4%–44.7% of placebo-treated subjects), but were generally mild or moderate. Eight to 19.6% of eslicarbazepine treated patients discontinued due to AEs (compared to 3.9%–8.5% of placebo-treated subjects). In these patients receiving combination anticonvulsant therapy, the most common AEs were dizziness, nausea and vomiting, somnolence, and diplopia. Eslicarbazepine is an effective and reasonably well-tolerated adjunct in patients with suboptimal control of their partial seizures.Keywords: eslicarbazepine, licarbazepine, voltage-gated sodium channel, partial-onset seizures, epilepsy |
| first_indexed | 2024-12-20T16:12:10Z |
| format | Article |
| id | doaj.art-5d97338a9a404842be4f68b31fa995c0 |
| institution | Directory Open Access Journal |
| issn | 1176-6336 1178-203X |
| language | English |
| last_indexed | 2024-12-20T16:12:10Z |
| publishDate | 2010-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-5d97338a9a404842be4f68b31fa995c02022-12-21T19:33:57ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2010-03-012010default103109Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizuresMartin E BrownRif S El-MallakhMartin E Brown, Rif S El-Mallakh1Department of Neurology, 2Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky, USAAbstract: Eslicarbazepine is a new dibenzazepine antiepileptic agent. It is a high affinity antagonist of the voltage-gated sodium channel. It is closely related to both carbamazepine and oxcarbazepine. Eslicarbazepine has similar affinity to inactivated sodium channels (channels in just activated neurons) as carbamazepine, and greater efficacy in animal models of seizure than oxcarbazepine. In human placebo-controlled trials of a single daily dose of eslicarbazepine added to other anti-epileptic agents, significant seizure reductions occurred with 800 and 1200 mg daily, with nearly half of the patients experiencing a greater than 50% reduction in seizure frequency. Adverse events (AEs) occurred in over 50% of patients receiving therapeutic doses of eslicarbazepine (compared to 31.4%–44.7% of placebo-treated subjects), but were generally mild or moderate. Eight to 19.6% of eslicarbazepine treated patients discontinued due to AEs (compared to 3.9%–8.5% of placebo-treated subjects). In these patients receiving combination anticonvulsant therapy, the most common AEs were dizziness, nausea and vomiting, somnolence, and diplopia. Eslicarbazepine is an effective and reasonably well-tolerated adjunct in patients with suboptimal control of their partial seizures.Keywords: eslicarbazepine, licarbazepine, voltage-gated sodium channel, partial-onset seizures, epilepsyhttp://www.dovepress.com/role-of-eslicarbazepine-in-the-treatment-of-epilepsy-in-adult-patients-a4060 |
| spellingShingle | Martin E Brown Rif S El-Mallakh Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures Therapeutics and Clinical Risk Management |
| title | Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures |
| title_full | Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures |
| title_fullStr | Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures |
| title_full_unstemmed | Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures |
| title_short | Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures |
| title_sort | role of eslicarbazepine in the treatment of epilepsy in adult patients with partial onset seizures |
| url | http://www.dovepress.com/role-of-eslicarbazepine-in-the-treatment-of-epilepsy-in-adult-patients-a4060 |
| work_keys_str_mv | AT martinebrown roleofeslicarbazepineinthetreatmentofepilepsyinadultpatientswithpartialonsetseizures AT rifselmallakh roleofeslicarbazepineinthetreatmentofepilepsyinadultpatientswithpartialonsetseizures |